ANNA BORNEMAN: Open Payments
NPI 1770101958 · CHATTANOOGA, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,142 in 52 payments from 12 companies in 2025. Trend: 2023 $992 · 2024 $1,273 · 2025 $1,142
Food & beverage: $1,142
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 9 | $227 |
| Novo Nordisk Inc | 11 | $224 |
| AstraZeneca Pharmaceuticals LP | 6 | $224 |
| Lilly USA, LLC | 9 | $134 |
| ABBVIE INC. | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Antares Pharma, Inc. | 2 | $45 |
| PFIZER INC. | 2 | $43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| Esperion Therapeutics, Inc. | 1 | $18 |
Products named: Veozah, AIRSUPRA, Rybelsus, MOUNJARO, Ozempic, FARXIGA, VRAYLAR, REXULTI.
Industry payments across TN — which companies pay providers there.
